INTRODUCTION
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm defined by the presence of BCR-ABL1 fusion, the result of the t(9;22)(q34;q11.2) translocation. Although the diagnosis of CML can be established on the basis of peripheral blood (PB) findings and identification of BCR-ABL1, bone marrow (BM) aspiration is still integral to the workup of a patient with suspected CML because it provides material for the histopathologic evaluation of the disease phase and determination of the karyotype and is useful for molecular studies. 1, 2 The BM blast percentage remains an important feature in determining the disease phase of CML-chronic phase (CP), accelerated phase (AP), or blast phase (BP)-although these definitions have evolved over time. 1, [3] [4] [5] [6] Blast counts usually can be determined by an assessment of BM aspirate smears. When BM smears are inadequate, often because of fibrosis or technical reasons, blasts counts determined by BM aspiration and biopsy can be discrepant. In such situations, a BM biopsy specimen can provide diagnostic information by allowing an assessment of a touch imprint, an overall assessment of the medullary space, and/or an immunohistochemical analysis of the biopsy specimen to delineate the blast count (eg, CD34 expression).
Cancer October 1, 2018 Recently, the utility of BM biopsy in the diagnostic workup of patients with suspected CML has been questioned. Furthermore, monitoring of the disease response in the era of highly effective tyrosine kinase inhibitor (TKI) therapy is primarily, but not exclusively, based on the level of BCR-ABL1 transcripts. Some investigators have suggested that the evaluation of a BM aspirate along with cytogenetic and/or molecular studies is sufficient to establish the diagnosis and monitor patients with CML. The new National Cancer Center Network (NCCN) guidelines mention BM biopsy, but indications for performing BM biopsy are not provided. 6, 8, 9 At our institution, we routinely perform BM aspiration and biopsy on all patients with CML at the time of their initial presentation. The goal of this retrospective review of a large cohort of consecutive patients with CML was to assess the contribution of core biopsy to the diagnostic workup and, more specifically, assess what potential value is added by BM core biopsy. The data suggest that BM biopsy is essential or helpful in the workup of approximately 25% of patients with CML.
MATERIALS AND METHODS

Patients
We retrospectively reviewed BM aspirate smears and core biopsy specimens of a large cohort of patients with CML at our institution between 2010 and 2016. Patients with CML of any phase were included. Patients with BCR-ABL1-positive acute myeloid leukemia or mixedphenotype acute leukemia without a documented history of CML were excluded. 1, 10 Clinical information and BM morphology at the time of the initial diagnosis or first presentation to our institution were reviewed. The medical records were reviewed for TKI use before the BM assessment at our institution. Because the first response assessment is performed 3 months after the initiation of TKI therapy, we considered patients who received TKI therapy for less than 3 months from the time of an outside diagnosis to the BM assessment at our institution to be treatment-naive. 6, 9 The study was conducted under a protocol approved by the institutional review board of The University of Texas MD Anderson Cancer Center and in accordance with the Declaration of Helsinki. Patients provided written informed consent to be included in the study.
Definition of BM Utility
All patients with CML at our institution at the time of presentation routinely undergo a BM evaluation that includes aspiration and core biopsy (unless not feasible).
BM aspirates were considered inadequate if no BM particles were present on any slides or if there was a predominance of mature neutrophils. A BM aspirate was considered suboptimal if only 1 particle with fewer than 500 BM cells was found in all available slides.
For each patient, BM biopsy was designated as essential, helpful, or noncontributory as follows: BM biopsy was considered to be essential when 1) the quality of the smears and clot section was either inadequate or suboptimal and blast counts required a touch imprint or CD34 immunohistochemical analysis of the biopsy specimen or 2) there was a discrepant blast count between the aspirate smears or touch imprint, so biopsy was required for the assessment of the CML phase by immunohistochemical analysis (CD34). An additional criterion used to consider BM biopsy essential was as follows: the patient had CML as a presumptive diagnosis, but biopsy was required to exclude other processes because of an unrelated disease diagnosis, such as a metastatic tumor or lymphoma (often requiring immunohistochemistry for keratin, CD3, and CD20).
BM biopsy was considered helpful when immunohistochemistry was vital for assessing non-CML-related findings such as lymphoid aggregates (CD3 and CD20) or quantifying megakaryocytes (CD61). BM biopsy was considered noncontributory if it did not fulfill the criteria to be classified as either essential or helpful.
Molecular and Cytogenetic Studies
Conventional chromosome analysis was performed on G-banded metaphases prepared from unstimulated 24-and 48-hour BM aspirate cultures with standard techniques. 11 The results were reported with the 2016 International System for Human Cytogenetics Nomenclature as described previously. 12 For patients with CML for whom BM biopsy was essential or helpful, the karyotype was stratified into groups with favorable, neutral, or poor cytogenetic risk according to findings reported previously.
2,13,14
BCR-ABL1 transcripts and cytogenetic studies were determined at diagnosis and every 3 months for a response assessment. BCR-ABL1 was detected by quantitative reverse transcriptase-polymerase chain reaction methods with RNA extracted from BM or PB samples as described elsewhere. 15, 16 A major molecular response (MMR) was defined as a BCR-ABL1/ABL1 ratio < 0.1% on the international scale, and a complete cytogenetic response (CCyR) was defined as no Philadelphia chromosome-positive metaphases in 20 metaphases by conventional karyotyping
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Statistical Analysis
Outcomes of interest included MMRs and CCyRs. For patients with BM aspirates and biopsy specimens, the response rates were compared between patients for whom staging was possible with an aspirate alone and patients for whom biopsy was essential or helpful. The latter group also was assessed by disease phase (CP or AP/BP) with Fisher's exact test. The Spearman rank correlation was used to assess the association between BCR-ABL1 transcript levels in PB and BM. Fisher's exact test was used to compare the proportions of patients with grade 2 or 3 myelofibrosis (MF) in AP/BP and CP phases within the subgroup of patients for whom BM biopsy was essential/helpful for staging. All statistical analyses were performed with R 3.4.0. All statistical tests used a significance level of 0.05%. No adjustments for multiple testing were made.
RESULTS
A total of 528 consecutive patients with CML presented at our institution during the study interval: 508 (96%) underwent BM aspiration and biopsy and formed the study cohort. Twenty patients (4%) underwent BM aspiration alone as a part of the initial workup, and this group was not further evaluated. In 127 of the 508 patients (25%), BM biopsy was either essential (109 patients) or helpful (18 patients) for the diagnostic evaluation of CML. We compared the demographic characteristics, BM morphologic, cytogenetic, and molecular features, and CML evolution between patients with essential BM biopsy specimens and patients with helpful BM biopsy specimens, and no differences were found. We, therefore, combined these categories into a single group for some analyses. The remaining 381 patients with CML for whom BM biopsy did not add diagnostic information were considered as a control group.
We evaluated the clinicopathologic features of the 127 patients with an essential or helpful BM biopsy to identify characteristics that could potentially predict the need for BM biopsy ( Table 1 ). The median age of this group was 49 years (range, 20-85 years), and 78 (61%) were women. Ninety-nine patients (78%) were therapynaive, and 28 patients (22%) were on TKI therapy. According to the standard cytogenetic results, 91 patients (72%) had standard-risk cytogenetic results, 19 (15%) had good-risk cytogenetic results, and 17 (13%) had lowrisk cytogenetic results.
In the group of 127 patients for whom BM biopsy was essential or helpful, 60 patients (47%) had inadequate BM aspirate smears with differential cell counts available only on the touch imprint. The remaining 67 patients (53%) had suboptimal aspirate smears. In this subgroup, 53 patients required immunohistochemistry on the BM biopsy; 30 required an assessment of CD34 to determine the blast count. In 17 patients, reticulin and trichrome stains for the assessment of MF were required for better morphologic characterization and a differential diagnosis with other myeloproliferative neoplasms. Two patients required other types of studies related to a history of Waldenstrom macroglobulinemia and a solid tumor. Neither of these patients had evidence of lymphoma or a solid tumor, and no patient was found to have an incidental second malignancy. Lastly, lymphoid markers were assessed in 3 patients, and megakaryocytic markers were assessed in 1 patient. One reason for a suboptimal or inadequate BM aspirate is the presence of MF. We, therefore, assessed reticulin and trichrome stains in the BM core biopsy; 110 of the 127 patients (87%) had reticulin and trichrome stains available. Of these, 67 had grade 0 or 1 MF, and 43 (39%) had grade 2 or 3 MF. In comparison, 115 patients (30%) in the control group had stains available for MF assessment. The frequency of MF grades 2 and 3 was lower in the control group than the BM essential and helpful groups (18 patients [16%] vs 43 patients [39%]; P = .0001). The frequency of high-grade MF was higher among patients with AP/BP CML than patients with CP CML (16 of 22 patients vs 27 of 88 patients; P = .0005; Fig. 1 ).
CML Phase
Fifty-four of 528 patients (10%) had AP/BP CML at their first assessment. BM biopsy was essential or helpful for 24 patients (12 AP patients and 12 BP patients) and was not required for 30 patients. The frequency of AP/BP was higher in the essential or helpful group than the control group (24 of 127 vs 30 of 381; P = .0013). For identification of the CML phase as at least AP, PB counts were sufficient in 20 of 24 patients (83%). In the remaining 4 patients (17%), AP was not evident in the PB counts, and BM aspiration and biopsy were required for recognition of AP disease. Among these 4 patients, 2 showed MF-2, 1 showed MF-1, and 1 did not show fibrosis. CD34 immunohistochemistry was required in 2 patients (50%): one with MF-2 and the other without fibrosis.
Twelve of 127 patients (9.4%) with an essential or helpful BM biopsy specimen had BP disease. Three patients were accurately classified by PB counts, and 9 patients required BM biopsy to distinguish AP from BP: 5 patients showed MF-2, 2 patients showed MF-3, and 2 patients showed MF-1. CD34 immunohistochemistry was required in 5 patients (56%): 3 had MF-2, and 2 had MF-1. The proportion of patients for whom BM biopsy was necessary for classification was significantly higher for patients with BP disease (P = .001 [Fisher's exact test]). Interestingly, 2 patients who had CP CML at the first assessment experienced progression to AP/BP disease during follow-up. In both cases, at the time of progression, the BM biopsy was essential for establishing the disease phase as AP/BP.
Initial BCR-ABL1 quantitative polymerase chain reaction data were available for 123 patients. The most common transcript type was either b2a2 (e13a2) or b3a2 (e14a2); 2 patients had e1a2 transcripts (190-kDa product). Fifty-seven patients had an assessment of BCR-ABL1 transcripts in PB with a median BCR-ABL1 ratio of 50.22; 13 patients had an assessment of BCR-ABL1 transcripts in BM with a median BCR-ABL1 to ABL1 transcript ratio of 51.
Higher MF Scores Correlate With Lower Rates of MMR
In the entire cohort of patients with an available BM biopsy specimen, 129 patients had not received TKI therapy and had follow-up allowing an assessment of their response. This subset included 55 patients with an essential or helpful BM and 74 patients in the control group. We analyzed the MMR and CCyR to TKI therapy in patients with CP CML and patients with AP/BP CML separately. For patients in AP/BP (n = 10), there were no differences in MMR or CCyR rates with respect to the MF score in BM (P = .9 and P = .9, respectively). Among patients with CP CML with available data for CCyR (n = 118) and MMR (n = 119), a significant difference in MMR was found between the patients with low and high MF scores (88 of We also evaluated for differences between patients who had an essential or helpful BM biopsy and control patients. In AP disease, no difference in MMR (P = .9) or CCyR (P = .9) was identified. In CP disease, no difference in MMR (P = .61) or CCyR (P = .58) was found. There was also no difference in survival (35 vs 39.5 months; P = .6).
Follow-Up BM Biopsy Is Required When the First CML Assessment Is Inadequate
One of the principal indications for BM biopsy assessment in this study was AP/BP disease. These patients also showed a significantly higher frequency of highgrade MF. On the basis of these findings, we explored the potential value of BM biopsy during the follow-up interval. Of 127 patients with an essential or helpful BM biopsy, 90 (71%) had a follow-up BM assessment available at our institution; the median number of BM samples during follow-up was 5 (range, 1-16) over a median of 36 months (range, 1-78 months). Forty-three patients underwent only BM aspiration, and 47 patients had at least 1 BM core biopsy during the follow-up. In 55% of the patients, at least 1 BM aspirate sample was inadequate for diagnosis. In 31 patients (34%), all follow-up BM aspirates were inadequate for diagnosis.
DISCUSSION
We report the results of a large study investigating the utility of BM biopsy in the workup of patients with CML in the TKI era. At our institution, BM core biopsy is performed routinely for newly diagnosed patients with CML, and this allowed us to retrospectively assess the potential added value of BM core biopsy. Because these patients were annotated with clinical, morphologic, molecular, and cytogenetic data as well as responses to therapy, we also investigated the relative prognostic impact of these variables and focused on identifying clear indications for performing BM biopsy. The results of this study indicate that clinical or laboratory variables suggestive of progression should alert clinicians to the need for performing BM biopsy as a part of the initial assessment of a patient with CML. Our analysis also suggests that inadequate BM aspirates among these patients often can be explained by the presence of MF.
The most recent NCCN guidelines recommend both BM aspiration and biopsy, and this highlights the importance of morphologic review and cytogenetic studies necessary for establishing the diagnosis of CML. 6 Nonetheless, indications for BM biopsy in patients with suspected CML have not been described extensively. Our findings suggest that indications for BM biopsy in patients with CML at first assessment include clinical findings suggestive of progressive disease, PB findings suggestive of AP/BP, a normal to mildly elevated white blood cell (WBC) count, absolute basophilia, and an absence of BM particles at the moment of aspirate collection. Interestingly, this group of patients with CML often required BM biopsy to adequately assess the BM during the follow-up interval.
BM aspiration is required for all patients in whom CML is suspected because its assessment confirms the diagnosis (eg, by cytogenetic and molecular analysis) and provides information needed for staging (ie, blast and basophil percentages). 1, 18 In this study, BM biopsy was more often needed in patients with AP/BP disease.
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The presence of high-grade MF was more frequent in these patients (71%; P = .005), and the identification of BP disease required a BM biopsy assessment in approximately 75% of these patients (P = .001). Follow-up specimens from these patient subsets also showed a higher frequency of inadequate BM aspirates. As evidenced by these results, BM biopsy at first assessment and follow-up is required for patients with criteria for AP/BP disease or with a clinical history suggestive of disease progression.
For the identification of AP disease, BM aspiration and biopsy with CD34 immunohistochemistry to assess blasts were required for approximately 20% of patients. The prognostic and therapeutic implications when AP disease is identified make it mandatory that these cases be identified promptly. In patients in whom AP disease is suspected and the PB findings do not reach the threshold, biopsy with CD34 immunohistochemical analysis is required. Similarly, in BP disease, more than half of these patients required CD34 immunostaining on the BM biopsy specimen to determine the blast count.
Conventional cytogenetic assessment is performed routinely on BM aspirate samples of patients with CML, as described in all guidelines and treatment studies in the TKI era. 6, 9, [19] [20] [21] In this study, all cytogenetic analyses were performed on BM aspirates. Nonetheless, because of the disease phenotype and high WBC counts in most patients, PB can be used as source for cytogenetic studies. Large cytogenetic studies comparing BM with PB as a metaphase source are required to identify PB as an appropriate source for conventional cytogenetic analysis.
An assessment of MF at diagnosis is not included in the most recent NCCN nor World Health Organization classification guidelines. 1, 6 In this study, high-grade MF could explain the need for BM biopsy in approximately 25% of the patients with CML and significantly correlated with decreased rates of MMR in the first year of TKI therapy. The remaining patients with CML had grade 0 or 1 MF, which suggested a better prognosis (Fig. 1) . Therefore, we recommend that patients with CML for whom BM biopsy at the first BM assessment is indicated should be evaluated for MF with reticulin and trichrome stains.
Others have described CML in a pre-CML phase. Patients with this diagnosis typically present with normal to mildly elevated WBC counts and absolute basophilia. Assessing the microvascular density (highlighted by CD34 immunohistochemistry) and the percentage of small, hypolobated megakaryocytes in the BM can reveal whether the process is pre-CML or a leukemoid reaction. Thus, BM biopsy is important in identifying patients with pre-CML not only because it yields blast counts but also because of its utility in distinguishing pre-CML from other diseases and from a leukemoid reaction. 22 With respect to prognosis, the Sokal score was developed in the chemotherapy era, and the Euro score was developed in the interferon-α era, with survival as the endpoint for both scores. 8 In the TKI era, there are 2 scores, the European Treatment and Outcome Study (EUTOS) score, which identifies the chance of achieving a CCyR after 18 months of TKI therapy, and the EUTOS longterm survival score, which considers CML-related deaths only. Neither of these scores includes BM information or BM blast counts. The patients for whom BM biopsy was essential or helpful in this study represented approximately 25% of this cohort. These findings further support the need for NCCN, European Society for Medical Oncology, and European LeukemiaNet guidelines to include indications for BM biopsy as part of the first assessment of patients with suspected CML who meet the indication. The findings also suggest that patients who require BM biopsy at their first assessment should undergo follow-up BM biopsy to ensure accurate CML staging.
This study has some limitations, including the retrospective nature of the analysis and the relatively small cohort size in the follow-up period. We also acknowledge that the absence of findings such as CD34-positive clusters of blasts and MF, although they provide value, cannot be evaluated as useful in this study design. We also excluded patients with another diagnosis who presented with suspected findings of CML. Hence, we think that it is likely that the utility of BM biopsy is underestimated in this study. However, this is the largest study of patients with CML in whom the role of BM biopsy has been evaluated, and our results may provide a basis for future prospective studies to validate the indications for BM biopsy suggested.
In summary, our findings support the use of BM biopsy as an important tool in the workup of a patient with suspected CML. BM biopsy is required for the initial staging of CML in approximately 25% of patients suspected of having the disease. BM biopsy is also indicated for patients who meet any of the criteria for AP/ BP CML, for patients who have a clinical history suggestive of disease progression (eg, a large spleen size), for patients with a normal or mildly elevated WBC count and absolute basophilia at presentation, and for patients for whom BM aspiration at their first assessment yields no BM particles. The requirement for BM biopsy in patients with suspected CML is mainly related to the increased frequency of MF and correlates with a decreased MMR rate in the first year of TKI therapy. Patients
Cancer October 1, 2018 with CML who require BM biopsy at the time of their initial diagnostic assessment will also likely require BM biopsy for subsequent BM assessments. Overall, the presented findings support including BM biopsy and indications for performing BM biopsy in updated CML guidelines. 
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